Semaphorin 3F (SEMA3F) influences patient survival in esophageal adenocarcinomaKarl Knipper(University Hospital Cologne), Thomas Schmidt(University Hospital Cologne)Scientific ReportsSeptember 4, 202410.1038/s41598-024-71616-8Cited by 3SaveCiteExport RISWatch citationsRelated PapersLoss of Argininosuccinate Synthetase-1 (ASS1) Occurs in Esophageal Adenocarcinoma and Represents a Promising Biomarker for Therapy with Pegargiminase|Cancers|2025|0